NR 546 Week 8 Dementia Medication Table Latest Update 2024 A+.

NR 546 Week 8 Dementia Medication Table Latest Update 2024 A+. Drug Name and Class FDA Indication (include stages ) Neurotransmitters Affected/Mechanism of Action Target Symptoms Short-acting, intermediate-acting, or long-acting. Duration of Action and Half-life (T1/2), CYP 450 enzyme Notable Side Effects/Precautions /Patient Education Instructions Donepezil (Aricept) Alzheimer’s disease – mild, moderate, and severe Acetylcholine enzyme inhibitor Reversibly but noncompetitively inhibits centrally acting acetylcholinesterase to make more Ach available. Increase Ach compensates in part for degenerating cholinergic neurons in neocortex that regulate memory Does not inhibit butyrylcholinesterase May release growth factors or interfere with amyloid deposition Targets memory loss in Alzheimers, behavioral symptoms in Alzheimers, Metabolized by CYP450 2D6 and CYP450 3A4 Elimination half-life approximately 70 hours Nausea, diarrhea, vomiting, appetite loss, increased gastric acid secretion, weight loss, insomnia, dizziness May exacerbate asthma or pulmonary disease. Increased gastric secretion may increase the risk of ulcers, bradycardia or heartblock may occur in patients with or without cardiac impairment. Dramatic reversal of symptoms not generally seen with cholinesterase inhibitors. Treats behavioral and psychological symptoms of Alzheimers dementia as well as cognitive symptoms. Taper to avoid withdrawal. Discontinuation of medication may lead to notable deterioration in memory and behavior which may not be restored when drug is restarted or another cholinesterase inhibitor is initiated. NR 546 Week 8 Dementia Medication Table Latest Update 2024 A+. memory loss in other demetias .